BRPI0919975A2 - imunoensaio para galectina-3 - Google Patents

imunoensaio para galectina-3

Info

Publication number
BRPI0919975A2
BRPI0919975A2 BRPI0919975A BRPI0919975A BRPI0919975A2 BR PI0919975 A2 BRPI0919975 A2 BR PI0919975A2 BR PI0919975 A BRPI0919975 A BR PI0919975A BR PI0919975 A BRPI0919975 A BR PI0919975A BR PI0919975 A2 BRPI0919975 A2 BR PI0919975A2
Authority
BR
Brazil
Prior art keywords
galectin
immunoassay
Prior art date
Application number
BRPI0919975A
Other languages
English (en)
Inventor
Pieter Muntendam
Original Assignee
Bg Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bg Medicine Inc filed Critical Bg Medicine Inc
Publication of BRPI0919975A2 publication Critical patent/BRPI0919975A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0919975A 2008-10-29 2009-10-29 imunoensaio para galectina-3 BRPI0919975A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10936608P 2008-10-29 2008-10-29
PCT/US2009/062616 WO2010096126A1 (en) 2008-10-29 2009-10-29 Galectin-3 immunoassay

Publications (1)

Publication Number Publication Date
BRPI0919975A2 true BRPI0919975A2 (pt) 2015-12-15

Family

ID=41445468

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919975A BRPI0919975A2 (pt) 2008-10-29 2009-10-29 imunoensaio para galectina-3

Country Status (10)

Country Link
US (4) US20100143954A1 (pt)
EP (2) EP2359143A1 (pt)
JP (2) JP5903270B2 (pt)
KR (1) KR101678703B1 (pt)
CN (2) CN102257390B (pt)
AU (1) AU2009340423B2 (pt)
BR (1) BRPI0919975A2 (pt)
CA (1) CA2742265C (pt)
MX (1) MX2011004501A (pt)
WO (1) WO2010096126A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
EA201270316A1 (ru) * 2009-08-25 2012-09-28 БиДжи МЕДИСИН, ИНК. Галектин-3 и сердечная ресинхронизирующая терапия
WO2011148668A1 (ja) * 2010-05-25 2011-12-01 株式会社 島津製作所 大腸がんマーカーガレクチン、採血試料中のガレクチン濃度の分析方法及び大腸がんマーカーガレクチン検出キット
US20120220671A1 (en) * 2011-01-31 2012-08-30 Bg Medicine, Inc. Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome
CN102226809B (zh) * 2011-02-13 2014-09-17 倪润洲 检测Galectin-3的时间分辨免疫荧光试剂盒
CN103718046B (zh) * 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
WO2013169890A1 (en) * 2012-05-08 2013-11-14 Bg Medicine, Inc. Systems and methods for assessing disease risk, status, and prognosis
WO2014052803A2 (en) * 2012-09-27 2014-04-03 Siemens Healthcare Diagnostics Inc. Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension
CN106796243B (zh) * 2014-08-14 2018-10-12 国立大学法人广岛大学 判定早产和/或低体重儿生育的风险的方法和用于该方法的试剂盒
US20170363620A1 (en) 2016-06-17 2017-12-21 Abbott Laboratories BIOMARKERS TO PREDICT NEW ONSET HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)
CN107383192B (zh) * 2017-07-19 2018-08-24 深圳市倍诺博生物科技有限公司 半乳糖凝集素-3检测试剂盒
CN111201030B (zh) * 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
EP3466975A1 (en) 2017-10-05 2019-04-10 Laboratoire Français du Fractionnement et des Biotechnologies A specific binding molecule directed against galectin-3 protein
EP3802582A4 (en) * 2018-06-07 2022-06-15 Palleon Pharmaceuticals Inc. MULTIMERIC PROTEINS FOR DETECTING A CARBOHYDRATE AND/OR TREATMENT OF A SIGLEC MEDIATED DISORDER
KR20210124308A (ko) * 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN119930824A (zh) * 2020-01-13 2025-05-06 真和制药有限公司 抗Gal3抗体和使用方法
CN113406332A (zh) * 2020-03-17 2021-09-17 中国医学科学院药物研究所 用于人Galectin-3含量检测的ELISA荧光检测试剂盒
JP7421400B2 (ja) * 2020-03-30 2024-01-24 アークレイ株式会社 ヒトガレクチン－３の分析、検出、測定に関する抗体、方法及びキット
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN111537744B (zh) * 2020-05-26 2023-04-07 上海交通大学医学院附属上海儿童医学中心 一种基于乳脂肪球膜特性的乳凝集素或粘蛋白1的elisa定量检测方法
WO2022158554A1 (ja) * 2021-01-22 2022-07-28 味の素株式会社 二量体化した環状ペプチドをスクリーニングする方法
CN115902204A (zh) * 2022-09-23 2023-04-04 北京大学第三医院（北京大学第三临床医学院） 一种外泌体形式半乳糖凝集素9的检测方法与试剂盒
CN118978593B (zh) * 2023-11-07 2025-07-15 深圳市睿盟创新生物科技有限公司 人半乳糖凝集素-3蛋白水平的测定方法及应用
CN118812696A (zh) * 2024-08-21 2024-10-22 南通大学附属医院 Galectin-3抗原表位肽、抗原、抗体及化学发光试剂盒

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) * 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US20010051350A1 (en) * 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
US6210976B1 (en) * 1997-06-10 2001-04-03 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU4055000A (en) * 1999-04-13 2000-11-14 Daniel K. Hsu Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
US7186681B2 (en) * 2000-03-13 2007-03-06 La Jolla Institute For Allergy And Immunology Methods of modulating cell migration using galectin-3
KR100395254B1 (ko) * 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
AU2002220266A1 (en) * 2000-11-09 2002-05-21 Millennium Pharmaceuticals, Inc. Methods for the identification and the treatment of cardiovascular disease
US7041449B2 (en) * 2001-03-19 2006-05-09 Wisconsin Alumni Research Foundation Methods of screening for compounds that inhibit expression of biomarker sequences differentially expressed with age in mice
CA2488850A1 (en) * 2001-06-08 2002-12-19 Mandalmed, Inc. Sustained release n-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating cancer
US20060019235A1 (en) * 2001-07-02 2006-01-26 The Board Of Trustees Of The Leland Stanford Junior University Molecular and functional profiling using a cellular microarray
US7447594B2 (en) * 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20060141493A1 (en) * 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
US20050014198A1 (en) * 2002-07-11 2005-01-20 Leong Ng Assays and kits for detecting and monitoring heart disease
CA2505416A1 (en) * 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
JP2004198313A (ja) * 2002-12-19 2004-07-15 Shusuke Inohara 甲状腺腫瘍の診断用キット
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US6889083B2 (en) * 2003-04-21 2005-05-03 Medtronic, Inc. Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
US20070105105A1 (en) * 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2004111654A2 (en) * 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
DE10347436B4 (de) * 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
WO2006102497A2 (en) * 2005-03-22 2006-09-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
EP1874930B1 (en) * 2005-04-12 2011-09-07 Université Libre de Bruxelles Use of a galectin-1-trageted rnai-based approach for the treatment of cancer
US7632634B2 (en) * 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
CA2650267A1 (en) * 2006-05-05 2007-11-15 Universiteit Maastricht / Carim Peptides for use in diagnosing the presence of ruptured atherosclerotic lesions in an individual
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
US7536428B2 (en) 2006-06-23 2009-05-19 Microsoft Corporation Concurrent read and write access to a linked list where write process updates the linked list by swapping updated version of the linked list with internal list
UA22569U (en) * 2006-11-29 2007-04-25 V P Komisarenko Inst Of Endocr Method for diagnosing papillary carcinoma of the thyroid gland
EA201270316A1 (ru) * 2009-08-25 2012-09-28 БиДжи МЕДИСИН, ИНК. Галектин-3 и сердечная ресинхронизирующая терапия
EP2568294B1 (en) * 2009-11-13 2015-01-07 BG Medicine, Inc. Risk Factors and Prediction of Myocardial Infaraction
EP2588111A1 (en) * 2010-07-02 2013-05-08 BG Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
US20120220671A1 (en) * 2011-01-31 2012-08-30 Bg Medicine, Inc. Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome

Also Published As

Publication number Publication date
EP2359143A1 (en) 2011-08-24
CA2742265A1 (en) 2010-08-26
MX2011004501A (es) 2011-11-18
KR101678703B1 (ko) 2016-11-23
JP2012507724A (ja) 2012-03-29
JP5903270B2 (ja) 2016-04-13
KR20110104930A (ko) 2011-09-23
AU2009340423A1 (en) 2010-08-26
CN104198712A (zh) 2014-12-10
JP2014199261A (ja) 2014-10-23
CN102257390B (zh) 2015-04-01
US20170370944A1 (en) 2017-12-28
CA2742265C (en) 2014-07-15
AU2009340423B2 (en) 2014-07-24
CN102257390A (zh) 2011-11-23
US20100143954A1 (en) 2010-06-10
EP3971570A3 (en) 2022-11-09
EP3971570A2 (en) 2022-03-23
WO2010096126A1 (en) 2010-08-26
US20240103018A1 (en) 2024-03-28
US20200033367A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0907237A2 (pt) Anticorpo anti-cldn6
PT2853545T (pt) Anticorpo específico para ige
DE602009000328D1 (de) Parallelmechanismus
BRPI0812818A2 (pt) Turbo-reator para aeronave
BRPI0920069A2 (pt) biomarcadores
BRPI1011791A2 (pt) montagem para perfuração de fundo de poço
EP2265642A4 (en) BIOMARKERS
BRPI0817427A2 (pt) Anticorpo anti-bst2
EP2263086A4 (en) BIOMARKERS
BRPI0905074A2 (pt) Desidratador
BRPI0812961A2 (pt) estrutura para acondicionamento
EP2265641A4 (en) BIOMARKERS
BRPI0807650A2 (pt) Fecho rosqueado para conexão rosqueada
ES1065835Y (es) Caperuza para cetreria
ES1070148Y (es) Macolla para barrotes mejorada
ES1066304Y (es) Bisagra para canapes
ES1067523Y (es) Tarima para alcorques
ES1063735Y (es) Testero para persiana
ES1065263Y (es) Captafaros para bionda
ES1066110Y (es) Tabique para la construccion
ES1066482Y (es) Pieza constructiva para paramento
ES1066306Y (es) Pieza para corseteria
ES1069144Y (es) Luminaria para guardarrail

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL